What is ThinkGenetic?
Founded in 2015 and headquartered in Virginia, ThinkGenetic operates at the forefront of health-tech innovation. The company specializes in deploying sophisticated AI-driven diagnostic tools designed to bridge the gap between symptomatic presentation and definitive genetic diagnosis. By streamlining the patient journey, ThinkGenetic provides essential support for both clinicians and individuals navigating the complexities of genetic disease, effectively positioning itself as a critical infrastructure provider in the precision medicine ecosystem. The firm's proprietary technology stack is engineered to parse vast datasets, ensuring that patients receive accurate insights faster than traditional diagnostic pathways allow.
How much funding has ThinkGenetic raised?
ThinkGenetic has raised a total of $2M across 2 funding rounds:
Other Financing Round
$1.5M
Other Financing Round
$500K
Other Financing Round (2019): $1.5M, investors not publicly disclosed
Other Financing Round (2021): $500K led by Ochsner Lafayette General Healthcare Innovation Fund
Key Investors in ThinkGenetic
Ochsner Lafayette General Healthcare Innovation Fund
A specialized investment vehicle focused on fostering innovation within the healthcare sector to improve patient outcomes and operational efficiency.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for ThinkGenetic?
With this recent infusion of capital, ThinkGenetic is well-positioned to scale its enterprise-level operations and expand its diagnostic reach. The strategic roadmap likely involves enhancing the predictive accuracy of its AI algorithms and forging deeper partnerships with healthcare systems to integrate its solutions into standard clinical workflows. As the company transitions into its next phase of growth, the focus will remain on scaling its technological footprint and solidifying its market position as a leader in AI-enabled genetic health solutions. This trajectory suggests a move toward broader commercialization and the potential for further integration into large-scale genomic research initiatives.
See full ThinkGenetic company page
